Article Text

Download PDFPDF

2022-RA-209-ESGO A retrospective study of ovarian cancer among elderly – evaluation and prognosis
  1. Miriam Rivka Brezis1,2,
  2. Shira Peleg Hasson3,2,
  3. Eliya Shachar3,2,
  4. Dan Grisaro2,4,
  5. Ido Laskov4,2,
  6. Nadav Michaan4,2,
  7. Lyri Adar3,
  8. Avigail Harpaz3,
  9. Adi Diner3,
  10. Bar Levy3,
  11. Ido Wolf3,2 and
  12. Tamar Safra3,2
  1. 1Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
  2. 2Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
  3. 3Division of Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
  4. 4Gynecolologic Oncology Unit, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel


Introduction/Background Half of epithelial ovarian cancer (EOC) are diagnosed above age 65. Women over 70 have higher morbidity and mortality. Our real-life retrospective study evaluates elderly with EOC.

Methodology Women above 70 were classified as ‘elderly’ (N=233) (71–93), and bellow 70 – ‘control cohort’ (N=755) (24–70). Treatment schedule used (6–8 cycles) were 3-weekly regimen (PC-3W) – carboplatin AUC-6 + Paclitaxel 175 mg/m2 on day 1 of a 21-day cycle, and weekly regimen (PC-1W) – carboplatin AUC-2 + paclitaxel 80 mg/m2 on days 1, 8, and 15 of a 28-day cycle

Results When comparing elderly to control median overall survival (mOS) was 41.26 (33.05–63.87) vs. 69.78 (50.07–75.01) months respectively (p<0.0001). No statistical differences were shown when comparing toxicities except for grade 2 anemia – 36.49% vs. 19.67% respectively (p<0.0001) and grade 2 alopecia – 44.81% vs. 60.52% respectively (p<0.0001). The use of PC-1W vs. PC-3W was 44.29% vs 47.14% in the elderly compared to 39.03% vs. 60.3% in the control (p<0.0001). Among the elderly mOS was 57.17 vs. 30.00 months for PC-1W and PC-3W respectively (p = 0.0075). No differences in toxicity were shown, when comparing PC-1W to PC-3W in elderly except for grade 2 alopecia – 26.21% vs. 65.18% respectively (p<0.0001), and grade 2 neuropathy – 20.19% vs. 36.61% respectively (p=0.0119)

Abstract 2022-RA-209-ESGO Figure 1
Abstract 2022-RA-209-ESGO Tabel 1

Abbreviations OS = overall survival, PFS = Progression free survival

Conclusion mOS is reduced in elderly, though better than expected, furthermore toxicity is tolerable in elderly. PC-1W was both more abundant and had better mOS in the elderly population. Therefore PC-1W regimen may offer advantages for elderly in terms of tolerance while retaining efficacy.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.